Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 121, Issue 6, 2014, Pages 700-705

  Cherry, N ^a   McNamee, R ^b   Heagerty, A ^b   Kitchener, H ^b   Hannaford, P ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cancer; estrogen; randomised controlled trial

Indexed keywords

ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DRUG EXPOSURE; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HEART REINFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVOR; UTERINE CERVIX CANCER;

CANCER; ESTROGEN; RANDOMISED CONTROLLED TRIAL;

AGED; ENDOMETRIAL NEOPLASMS; ENGLAND; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; RECURRENCE; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; WALES;

EID: 84899435973     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12598     Document Type: Article

References (9)

1. The Esprit team. Oestrogen therapy for the prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002; 360: 2001-8.
2. Marjoribanks J, Farquhar C, Roberts H, Lethaby A,. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;(7): CD004143.
3. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo controlled trial. Ann Intern Med 2001; 135: 939-53.
4. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
6. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-33.
7. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Margolis KL, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-14.
8. Medicines Control Agency (MCA) Committee on Safety of Medicines. New product information for hormone replacement therapy. Curr Probl Pharmacovigilance 2002; 28: 1-2.
9. Schierbeck LL, Rejnmark l, Tofteng CL, Stilgren L, Eiken P, Moselilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.